
Opinion|Videos|April 22, 2024
Axatilimab Trial Results
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































